Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia

ConclusionPatients with an e13a2 transcript demonstrate an inferior molecular response to imatinib in our regional population.
Source: BMC Hematology - Category: Hematology Source Type: research